N-Acetyl Epitalon Amidate: what the studies show, status and safety
Summary
N-Acetyl Epitalon Amidate is a sales name for Epitalon, a four-amino-acid research peptide, with a small chemical cap added at each end. Searches of seven literature, substance and trial databases found no study of this capped form, while control searches for Epitalon found it at once. A 2025 review states that such caps have not yet been evaluated for Epitalon. No approval was found in any market checked, no Epitalon dose can be carried over to it, and in sport it is banned at all times.
Key findings at a glance
- No study found in cells, animals or people. Seven databases were searched on 23 September 2026. The same PubMed run found 120 records for Epitalon, so the searches themselves work [1], [2], [3].
- Researchers say the idea is untested. A 2025 review notes that acetylation and amidation "can sometimes be employed" to stabilise short peptides. For Epitalon, it says, "this idea has not been evaluated yet" [4].
- No database record of its own found. The PubChem entry and the FDA code filed under "N-acetyl Epitalon" describe another molecule. It is capped at the front end only [5], [6].
- On sale since at least 2015. An archived shop page from 11 September 2015 offers the amidated form. Its product text describes Epitalon, not the capped molecule [7].
- A seller's own data point to plain Epitalon. One shop lists the registry number and formula of unmodified Epitalon for its "amidate" [8].
- Related research shows trade-offs. In other peptides, an amide cap barely slowed breakdown in human blood serum. An acetyl cap made the peptides less active [9].
- Banned in sport at all times. No approval was found anywhere, so category S0 of the 2026 Prohibited List applies. It is not named in the annex to the German Anti-Doping Act [10], [11].
What it is
N-Acetyl Epitalon Amidate is a trade name, not a scientific or official drug name. It describes Epitalon with two small chemical changes. Epitalon is a chain of four amino acids, the building blocks of proteins, and its own story is on the Epitalon page.
The first change is an acetyl group, a small chemical cap, attached to the start of the chain. The second turns the acid group at the end of the chain into an amide. Sellers present it as protection against breakdown in the body [12].
No university, institute or company was found to claim the molecule, and no paper introducing it was found [1], [2]. The 2002 patent on Epitalon covers the peptide and its salts, but names neither cap [13]. The structure below is taken from sellers' descriptions and has not been confirmed by any independent analysis found.
Quick facts
| Field | Value | Ref |
|---|---|---|
| Sales names | N-Acetyl Epitalon Amidate, NA-Epitalon Amidate, Ac-Epithalon-NH2 | [7], [14] |
| Sequence, as given by sellers | Ac-Ala-Glu-Asp-Gly-NH2, short form Ac-AEDG-NH2 | [14] |
| Parent substance | Epitalon, Ala-Glu-Asp-Gly, PubChem CID 219042 | [15] |
| Formula | C16H25N5O9, calculated from the sequence | [14], [15] |
| Mass | 431.40 g/mol, calculated; not registered in any database found | [15] |
| PubChem entry | None found; a search by chemical structure returned no record | [15] |
| FDA substance code (UNII) | None found; code UXR7AF6R4F belongs to the free-acid form | [6] |
| CAS registry number | None found | [16] |
| How long it lasts in the body | No published value found | [1] |
| Registered studies in people | None found | [3] |
| Approval status | No approval found in any market checked | [17], [18] |
| Earliest trace found | An American shop page, 11 September 2015 | [7] |
Five molecules, easily confused
| Form | Sequence | Formula | Molar mass | Database record |
|---|---|---|---|---|
| Epitalon | H-AEDG-OH | C14H22N4O9 | 390.35 g/mol | PubChem CID 219042, UNII O65P17785G [15], [6] |
| Epitalon acetate, a salt | H-AEDG-OH with acetic acid | C14H22N4O9 · C2H4O2 | 450.40 g/mol | Assessed by the FDA as a form of Epitalon [19] |
| N-acetyl Epitalon, free acid | Ac-AEDG-OH | C16H24N4O10 | 432.38 g/mol | PubChem CID 171390141, UNII UXR7AF6R4F [5], [6] |
| Epitalon amide | H-AEDG-NH2 | C14H23N5O8 | 389.36 g/mol | PubChem CID 177780893 [15] |
| N-Acetyl Epitalon Amidate | Ac-AEDG-NH2 | C16H25N5O9 | 431.40 g/mol, calculated | None found [15], [6] |
The capped forms differ from each other by about one mass unit, and their names by one word. A label reading "N-acetyl Epitalon" therefore does not say which molecule is meant.
How it works
This is unknown. No study found has tested what this molecule does in a cell, an animal or a person [1], [2]. What circulates instead are claims made by sellers, and each can be traced to where it came from.
- "Capping both ends makes it more stable." No stability measurement was found for this molecule. For Epitalon, a 2025 review says the idea "has not been evaluated yet" [4].
- "It is taken up better and lasts longer, so less is needed." An information site close to the trade makes this claim [12]. No data on uptake or breakdown were found for this molecule, and the FDA found none for Epitalon in any species [19].
- "It acts like Epitalon on telomerase and melatonin." Telomerase is an enzyme that maintains the ends of chromosomes, and melatonin is the sleep hormone. These are findings reported for Epitalon, carried over to a different molecule [8], [12].
- "It works as a nasal spray." Several shops sell it in this form [8], [20]. No study of nasal use of this molecule was found [1], [2].
The common thread is borrowing. In other peptides, small changes at the chain ends altered binding and breakdown [9], [21]. Findings about Epitalon therefore cannot simply be carried over. The related products N-Acetyl Semax Amidate and N-Acetyl Selank Amidate follow the same naming pattern and raise the same questions.
What the trials found
No trials were found. The searches found no registered or published study in people and no animal or cell experiment with this molecule [1], [2], [3]. The only peer-reviewed statement found on the question itself says that it has not been examined [4].
What researchers say about capping Epitalon
Review article In 2025, four researchers from two Polish universities published an overview of Epitalon research. They write that short peptides such as Epitalon "are typically unstable and degrade rapidly in vivo" [4].
They go on: "Chemical modifications like acetylation and amidation can sometimes be employed to enhance the stability of such peptides. However, to the best of our knowledge, in the case of Epitalon, this idea has not been evaluated yet." [4]
The searches described below reached the same result.
How the absence was checked
Each search was paired with a control search for Epitalon, which is well recorded. An empty result means that nothing was found under that name, not that the search failed. It does not prove that no work exists anywhere.
PubMed searches run on 23 September 2026. The control terms find 120 and 129 records in the same run; every search for the capped forms returns none. Source [1].
- PubMed. Every spelling of the name and of the capped sequence returned 0 records. Combined searches for Epitalon with acetyl or amide terms returned 1 record, about an enzyme in melatonin production, not the capped molecule. The controls returned 120 and 129 [1].
- Europe PMC, including full texts. Twelve spellings returned nothing. Epitalon combined with "acetylated" or "amidated" returned 11 records, none about a capped form. The control returned 100 [2].
- Patents. The Europe PMC patent index returned nothing for the capped forms. The control found 2 records, among them the 2002 Epitalon patent [2], [13].
- PubChem. A search by the exact chemical structure returned no record. The same kind of search found the amide-only form at once [15].
- FDA substance register. A search for Epitalon returned 2 entries: Epitalon and the free-acid form. No entry for the amidated form was found [6].
- ClinicalTrials.gov. Searches for the variant and for Epitalon returned 0 studies. The control search for semaglutide returned 786 [3].
- Wikidata. No entry was found for the variant; the control returned Epitalon's entry [22].
Some sources could not be searched automatically. They include Google Patents, Russian patent and science databases, and the CAS registry, so the result covers the seven databases listed above.
Evidence from other peptides
Capping has been tested in other peptides. These studies say nothing direct about this molecule, but they show that the effect of a cap is not predictable.
Laboratory study, other peptides In 2010, researchers tested short antimicrobial peptides in human blood serum. The amide cap made them more active against bacteria but made "little difference" to how fast they broke down. The acetyl cap made them more resistant to breakdown, but less active [9].
Cell study, other peptide In 2016, researchers compared Semax with its acetylated form. The acetyl cap changed how the peptide binds copper. In a line of human nerve-derived cells grown in a dish, acetylated Semax no longer protected against copper damage, unlike plain Semax [21].
Laboratory study, other peptide In 1986, researchers used end caps and amino acid swaps to make thymopentin, a five-amino-acid thymus peptide, resist breakdown. The versions shown to stay active and stable in human serum all had an amino acid swapped, so the caps were not tested alone [23].
Review A 2006 review of ways to prolong how long peptides last in the blood names changes to the chain ends as one option. It also names fast clearance by the kidneys as a common cause of short half-lives, which caps may not address [24].
What is still unknown
- Whether the molecule does anything at all in the body.
- How much reaches the bloodstream, and how long it stays.
- How the body breaks it down, and into which pieces.
- Whether it is toxic to any organ, in the short or the long term.
- Whether the two caps preserve, strengthen or abolish the properties reported for Epitalon.
- Whether products sold under the name contain this molecule at all.
Side effects and safety
No side-effect profile could be found, and that is not the same as being safe. No published study was found in which people or animals received the molecule, so no recorded side effects were found either [1], [3].
The clearest risk is identity. Sellers' own data contradict each other:
- One seller lists Epitalon's data for the "amidate". The registry number, formula and mass it gives belong to unmodified Epitalon [8].
- Another mixes the two capped forms. It names the sequence without the amide cap. The formula and mass it gives belong to the amidated form [25].
- A chemical catalogue entry holds no data. It has no formula and a molar mass of "0", yet lists sellers [16].
Whether goods sold under the name contain the capped molecule, plain Epitalon or something else cannot be checked from public data. No official or peer-reviewed laboratory analysis of goods sold under this name was found [1].
The FDA describes the same problem for Epitalon. It writes that it "has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name" [19]. It calls inconsistent naming a safety risk, because patients "may be dosed with a different bulk drug substance than the physician ordered" [19].
The safety questions raised for Epitalon itself are set out on the Epitalon page. They apply here at least as much, because no data on the capped form were found. Whether the caps change any of them is unknown.
What was not found
None of the following turned up in the searches described on this page:
- Toxicology of any kind, including effects on fertility, genes or long-term organ health.
- Data on uptake, breakdown, half-life or elimination.
- Data on immune reactions or on interactions with medicines.
- Data of any kind from people.
- A pharmacopoeia standard or an approved quality specification, which would give an agreed test for what a vial should contain.
Why this page lists no doses
Every dose in this register comes from a published study, with the population, the length of treatment and the source attached. No study of N-Acetyl Epitalon Amidate was found, so there is no study dose to report [1], [3].
Doses used in Epitalon research must not be carried over either. The FDA writes that "different active moieties are not interchangeable because they can have different safety and efficacy profiles" [19]. The capped form is a different molecule, and no study comparing the two was found.
Sellers argue the reverse: the variant is said to be more stable, so smaller amounts would suffice [12]. No measurement supporting that was found. Amounts on sales pages come from sales copy rather than studies, so they are not repeated here.
Development and approval status
From a patented tetrapeptide to a shop variant
- 2002Epitalon patent application publishedCovers the peptide and its salts; neither cap is named, ref [13]
- August 2015Acetylated Epitalon on sale onlineEarliest archived page of an American shop, ref [7]
- September 2015The amidated form appearsSame shop; the product text describes Epitalon, ref [7]
- 2019 to 2025More shops list itArchived product pages and images from several sellers, ref [20]
- May 2024Database record for the free-acid formPubChem entry from the FDA register; not the amidated form, ref [5]
- 2025Review: capping untested for EpitalonAcetylation and amidation of Epitalon described as not yet evaluated, ref [4]
- July 2026FDA advisory meeting on EpitalonAssesses Epitalon and Epitalon acetate only, ref [19]
- 23 September 2026Registers and databases searchedNo approval, study or record of its own found, refs [1], [17]
No development of N-Acetyl Epitalon Amidate was found. The searches found no sponsor, institute or programme, and no published experiment of any kind [1], [3].
- 2002 the Epitalon patent application claims the peptide and its salts, such as the acetate. It does not describe either cap [13].
- August 2015 an American online shop offers acetylated Epitalon, according to the earliest archived copy of its page [7].
- September 2015 the same shop lists the amidated form. Both product texts describe Epitalon word for word and add no data of their own [7].
- 2019 to 2025 more shops list the product, according to archived pages [20]. A Russian seller calls such capped peptides "new, promising structures" [14].
- July 2026 an FDA advisory committee considers Epitalon and Epitalon acetate. The capped forms were neither nominated nor assessed [19].
The same shop listed capped versions of Semax and Selank in 2015 too [7]. The name follows a pattern that sellers applied to one peptide after another.
| Market | Status | Note | Ref |
|---|---|---|---|
| United States | No approval found | No product or bulk listing; not nominated for pharmacy compounding | [18], [26] |
| European Union | No approval found | No entry in the European medicines dataset | [17] |
| Germany | No approval found | No EU approval; national database not queried | [17] |
| United Kingdom | No approval found | Database could not be queried; the FDA found no approval of Epitalon | [19] |
| Australia | No approval found | Database could not be queried; the FDA found no approval of Epitalon | [19] |
| Canada | No approval found | Drug database returned no entry | [27] |
| Switzerland | No approval found | Not in the list of authorised medicines | [28] |
| Russia | No registration found | Register not machine-readable | [29] |
The entries were checked on 23 September 2026, with a control search wherever a database could be queried. The controls found 10 European entries for semaglutide and 5 Swiss entries for Ozempic, and Canada's database returned an entry for Ozempic [17], [28], [27].
Three entries rest on narrower checks. The British and Australian findings are inferred, because those databases could not be queried automatically. The FDA found no approval of Epitalon itself in either country [19]. For Germany, no European approval was found, and no national database was queried [17].
Russia needs a note. The state register could not be read automatically, so this page asserts nothing about it [29]. Even for Epitalon, a Russian registration could not be verified, as the Epitalon page explains. No sign of a Russian drug history of the capped form was found [14].
In the United States, the FDA database lists 8 bulk ingredient entries for Epitalon or Epitalon acetate, and none for any capped form [18]. The general picture is under are peptides legal.
Anti-doping
N-Acetyl Epitalon Amidate is banned at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use" [10].
The variant is not named on the list, and no other section was found to cover it. No approval was found in any market checked, so the clause applies. All S0 substances count as specified substances, a technical category that affects how sanctions are handled [10].
In Germany the variant is not named in the annex to the Anti-Doping Act. The annex extends its entries to "derivatives", but only of the substances it lists, and neither Epitalon nor any variant is listed [11].
No published test for the capped form in blood or urine was found [1], [2]. The wider picture is at peptides banned in sport.
Compared with related peptides
Epitalon, its salt and three capped forms. The two capped forms differ by only 0.98 g/mol. The value for the amidated form is calculated, because no database record was found. Sources [15], [5], [19].
| Substance | What it is | Biological studies found | Named in the 2020 Belgian test method | Anti-doping |
|---|---|---|---|---|
| Epitalon | Parent peptide of four amino acids | Cell, animal and three human reports [19] | No [30] | S0 [10] |
| N-acetyl Epitalon, free acid | Epitalon with an acetyl cap only | None found [1] | No [30] | S0 [10] |
| N-Acetyl Epitalon Amidate | Epitalon capped at both ends | None found [1] | No [30] | S0 [10] |
| N-Acetyl Semax Amidate | Semax capped at both ends | None found | Yes [30] | S0 [10] |
| N-Acetyl Selank Amidate | Selank capped at both ends | None found | Yes [30] | S0 [10] |
The comparison is not about strength. It shows how far a trade product can sit from the peptide whose name it borrows. Epitalon has a database record, an FDA assessment and a research record that anyone can check. For the amidated variant, none of these was found.
Among the three capped siblings, this one is the thinnest case. A Belgian drug-control laboratory included the Semax and Selank variants as reference samples in a 2020 test method, but not this one [30]. For the Epitalon variant, not even analytical data were found.
Common misconceptions
- "N-acetyl Epitalon is just Epitalon acetate." It is not. Epitalon acetate is a salt of unchanged Epitalon. The acetyl cap is bonded to the chain and makes a different molecule [19], [5].
- "The Epitalon studies apply to it." No study of the capped form was found. A 2025 review states that capping Epitalon "has not been evaluated yet" [4].
- "Caps always make a peptide more stable and stronger." Not in general. In one study an amide cap barely slowed breakdown and an acetyl cap reduced activity; in another, acetylation removed a protective effect [9], [21].
- "The PubChem entry and FDA code show it is registered." Both belong to the free-acid form, without the amide cap. A UNII is only an identifier in a substance register, not an approval [5], [6].
- "A seller's registry number identifies it." At least one seller gives the registry number and formula of unmodified Epitalon for its "amidate" [8].
- "It is a research variant from the Epitalon laboratory." No scientific originator was found. The Epitalon patent covers its salts, not capped forms, and the earliest trace found is a shop page [13], [7].
Frequently asked questions
Are there any studies on N-Acetyl Epitalon Amidate?
None were found. Searches of seven databases on 23 September 2026 found no study in cells, animals or people, while the same PubMed run found 120 records for Epitalon. A 2025 review states that capping Epitalon "has not been evaluated yet".
Is N-Acetyl Epitalon Amidate the same as Epitalon?
No. It is Epitalon with a chemical cap at each end, which gives it a different formula and mass. Findings about Epitalon therefore say nothing reliable about the variant, and the FDA considers different active molecules not interchangeable.
Is N-Acetyl Epitalon Amidate more stable than Epitalon?
No measurement of that was found. The claim rests on studies of other peptides, where caps sometimes slowed breakdown and sometimes barely did. In one of those studies the acetyl cap also made the peptides less active.
What is the difference between N-acetyl Epitalon and N-Acetyl Epitalon Amidate?
The first carries only an acetyl cap at the start of the chain; the second is also changed at the end. Their masses differ by about one unit. A PubChem record and an FDA substance code were found only for the first, the free-acid form.
Is Epitalon acetate the same as N-acetyl Epitalon?
No. Epitalon acetate is a salt of unchanged Epitalon, the form the FDA assessed in 2026. N-acetyl Epitalon is a chemically changed molecule. The similar names make the two easy to confuse.
Who invented N-Acetyl Epitalon Amidate?
No university or company was found to claim it. The earliest trace found is an American online shop, which listed the acetylated form by August 2015 and the amidated form by September 2015. Its product text described Epitalon, with no data of its own.
Is N-Acetyl Epitalon Amidate approved as a medicine anywhere?
No approval was found in any of the eight markets checked on 23 September 2026. The FDA assessed only Epitalon and Epitalon acetate in 2026, and no bulk listing of the capped form was found in the United States.
Is N-Acetyl Epitalon Amidate banned in sport?
Yes, at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers substances that no health authority has approved for use in people, and no approval of this one was found. It is not named in the German Anti-Doping Act.
Why does this page list no doses for N-Acetyl Epitalon Amidate?
No study of it was found, so there is no study dose to report. Epitalon doses must not be carried over, because the variant is a different molecule and no study comparing the two was found. Amounts on sales pages are sales copy, not measurements.
Sources
- PubMed, NCBI E-utilities. Searches for "N-acetyl epitalon", "N-acetyl epithalon", "acetyl-epitalon", "Ac-AEDG", "AEDG-NH2", "Ac-Ala-Glu-Asp-Gly", "Ala-Glu-Asp-Gly-NH2", "Ac-Ala-Glu-Asp-Gly-NH2", "epitalon amide", "epithalon amide" and "epitalon amidate" (0 records); Epitalon or its sequence combined with acetyl or amide terms (1 record, PMID 22816096, on an enzyme of melatonin production and unmodified Epitalon); Epitalon combined with analogue, derivative or modification terms (12 records, none on a capped form); Epitalon combined with seized, counterfeit, internet or purity terms (1 record, on unmodified Epitalon); controls "epitalontiab OR epithalontiab OR epithalonetiab" (120) and "Ala-Glu-Asp-Gly" (129). Retrieved 23 September 2026. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi
- Europe PMC, REST search including full texts and the patent index. Twelve spellings of the capped forms, among them "N-acetyl epitalon", "acetyl epitalon", "Ac-AEDG-NH2", "Ala-Glu-Asp-Gly-NH2", "epitalon amide" and "NA-Epitalon" (0 records each); Epitalon combined with "acetylated", "N-acetyl", "amidated" or "amidation" (11 records, none on a capped form); control "epitalon" (100). Patent index: capped forms 0 records; control 2 records, including WO02090380. Retrieved 23 September 2026. https://www.ebi.ac.uk/europepmc/webservices/rest/search
- ClinicalTrials.gov, API v2. Searches for "N-acetyl epitalon", "epithalon amidate" and "epitalon" (0 studies each); control "semaglutide" (786). Retrieved 23 September 2026. https://clinicaltrials.gov/api/v2/studies
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences 26(6):2691. PMID 40141333. PMC11943447. DOI 10.3390/ijms26062691. Full text read, including the passage on acetylation and amidation. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
- PubChem. Compound CID 171390141, "N-Acetyl Epitalon", C16H24N4O10, 432.38 g/mol, notation Ac-Ala-Glu-Asp-Gly-OH: the acetylated form with a free acid end, not the amidated form. Created 22 May 2024; the only depositor is the FDA Global Substance Registration System. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/171390141
- FDA Global Substance Registration System. Search "epitalon": 2 entries, EPITALON (UNII O65P17785G) and N-ACETYL EPITALON (UNII UXR7AF6R4F, structure C16H24N4O10, 432.38, free acid end). No entry for the amidated form. Retrieved 23 September 2026. https://gsrs.ncats.nih.gov/api/v1/substances(UXR7AF6R4F)
- Internet Archive captures 20150826204011 of the product page "N-Acetyl Epitalon" (26 August 2015) and 20150911012835 of the product page "N-Acetyl Epitalon Amidate" (11 September 2015) at an American research-chemical shop, the earliest captures of those pages. Both texts describe Epitalon and cite no data of their own; both state that the compound "has not been approved by the FDA and should be used for research purposes only." The same shop's capture index holds an amidated Semax page from 6 February 2015 (capture 20150206051604) and an amidated Selank page from 8 October 2015 (capture 20151008013500). Retrieved 24 September 2026. Seller source, cited as evidence of what was on sale. Not linked.
- Seller product page for "N-Acetyl Epithalon Amidate" as a nasal spray, retrieved 23 September 2026. Gives CAS 307297-39-8, formula C14H22N4O9 and mass 390.35, which are the data of unmodified Epitalon, and attributes Epitalon's reported effects to the product. Seller source, cited as evidence of what is claimed. Not linked.
- Nguyen LT, Chau JK, Perry NA, de Boer L, Zaat SA, Vogel HJ (2010). Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One 5(9):e12684. PMID 20844765. DOI 10.1371/journal.pone.0012684
- World Anti-Doping Agency. The 2026 Prohibited List, in force from 1 January 2026, section S0, including "All prohibited substances in this class are Specified Substances." Full-text search for "epitalon", "epithalon" and "AEDG" returned no match. Retrieved 23 September 2026. https://www.wada-ama.org/en/prohibited-list
- Germany. Annex to section 2(3) of the Anti-Doping Act (Anti-Doping-Gesetz), Federal Law Gazette 2023 I No. 67, including the closing clause on salts, esters, isomers and derivatives of the listed substances. Epitalon and its variants are not listed. Checked 23 September 2026. https://www.gesetze-im-internet.de/antidopg/anlage.html
- Information website close to the trade, article comparing Epitalon, Epitalon amidate and N-acetyl Epitalon amidate, retrieved 23 September 2026. Claims greater stability, better uptake and a much smaller amount needed, and attributes Epitalon's reported effects to the capped forms, without citing a study of them. Seller-related source, cited as evidence of what is claimed. Not linked.
- Khavinson VKh (2002). Tetrapeptide stimulating the retinal function and the method of its application. International patent application WO02090380. Claims the tetrapeptide Ala-Glu-Asp-Gly and its pharmaceutically acceptable salts, such as the acetate; names no N-terminal acetylation and no C-terminal amidation. Found through the Europe PMC patent index.
- Russian seller pages, retrieved 23 September 2026: product page "Ac-Epithalon-NH2", giving the capped sequence and the formula C16H25N5O9 without a CAS number, and an article on acylation and amidation of peptides that calls such peptides "новые перспективные структуры" (new, promising structures). Seller source, cited as evidence of what is claimed. Not linked.
- PubChem, PUG-REST. Identity and connectivity searches for the structure of Ac-Ala-Glu-Asp-Gly-NH2 returned no record. Controls found by the same kind of search: CID 219042, Epitalon, C14H22N4O9, 390.35 g/mol, and CID 177780893, H-Ala-Glu-Asp-Gly-NH2, C14H23N5O8, 389.36 g/mol. Formula C16H25N5O9 and molar mass 431.40 g/mol calculated from the sequence with standard atomic weights. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/219042
- ChemicalBook, catalogue entry CB38378883 "n-acetyl Epitalon amidate": no formula, molar mass given as 0, no CAS number, offers from several sellers. Retrieved 23 September 2026. Catalogue source, cited as evidence of what is listed. Not linked.
- European Medicines Agency. Medicines output, medicines JSON report, 2,746 records: "epitalon", "epithalon" and "aedg" not found; control "semaglutide" 10 records. Germany was not queried in a national database. Retrieved 23 September 2026. https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json
- openFDA, NDC directory. "N-ACETYL EPITALON" as active ingredient and "N-acetyl epitalon" and "acetyl epithalon" as generic names: not found. Control "EPITALON": 8 bulk ingredient listings for Epitalon or Epitalon acetate. Retrieved 23 September 2026. https://api.fda.gov/drug/ndc.json
- FDA (2026). FDA Evaluation of Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate). Briefing document for the Pharmacy Compounding Advisory Committee meeting of 23 to 24 July 2026, dated 12 May 2026. Section II.A and Table 1 on salts, derivatives and active moieties; literature search on human use; pharmacokinetics; country screening. Retrieved 23 September 2026. https://www.fda.gov/media/193345/download
- Internet Archive capture index for the domains of several further sellers, queried 23 September 2026: product images in upload folders dated February 2017 and August 2019, captured in 2019 and 2021, and first captures of product pages between December 2023 and April 2025, some of them for nasal sprays. Seller sources, cited as evidence of what was on sale. Not linked.
- Magrì A, Tabbì G, Giuffrida A, Pappalardo G, Satriano C, Naletova I, Nicoletti VG, Attanasio F (2016). Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry 164:59-69. PMID 27586814. DOI 10.1016/j.jinorgbio.2016.08.013. Abstract read.
- Wikidata. Search for "N-acetyl epitalon" (no entity); control "epitalon" (Q27285389). Retrieved 23 September 2026. https://www.wikidata.org/wiki/Q27285389
- Heavner GA, Kroon DJ, Audhya T, Goldstein G (1986). Biologically active analogs of thymopentin with enhanced enzymatic stability. Peptides 7(6):1015-1019. PMID 3031628. DOI 10.1016/0196-9781(86)90131-2
- Werle M, Bernkop-Schnürch A (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30(4):351-367. PMID 16622600. DOI 10.1007/s00726-005-0289-3
- Seller product page "NA Epitalon", retrieved 23 September 2026. Gives the sequence N-Ac-Ala-Glu-Asp-Gly without the amide cap, but the formula C16H25N5O9 and 431.40 Da of the amidated form. Seller source, cited as evidence of what is claimed. Not linked.
- FDA. Bulk drug substances nominated for use in compounding under section 503A, as at 14 May 2026. Neither Epitalon nor any variant is listed; control entries present. https://www.fda.gov/media/94155/download
- Health Canada. Drug Product Database API: "epitalon", "epithalon" and "acetyl epitalon" returned empty results; control "ozempic" returned DIN 02471469. Retrieved 23 September 2026. https://health-products.canada.ca/api/drug/drugproduct/
- Swissmedic. List of authorised human medicines (XLSX): "epitalon", "epithalon" and "aedg" not found; control "ozempic" 5 entries. Retrieved 23 September 2026. https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html
- State Register of Medicines of the Russian Federation (GRLS). The query "эпиталон" on 23 September 2026 returned only the page framework without a result list. A mirror queried on 24 September 2026 returned no result list either, including for the control "семакс". https://grls.rosminzdrav.ru/GRLS.aspx
- Vanhee C, Francotte A, Janvier S, Deconinck E (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis 12(3):371-381. PMID 31667971. DOI 10.1002/dta.2717. Full text searched on 24 September 2026: it lists amidated Semax and amidated Selank as reference samples; "epitalon", "epithalon" and "AEDG" do not occur. https://sciensano.be/sites/default/files/dta_nootropic_peptides.pdf
Cite this page
The searches behind this page were run on 23 September 2026 and partly checked on 24 September 2026. For a substance known almost only from empty search results, the date is part of the finding itself.
myPeptides Research & Editing. (2026). N-Acetyl Epitalon Amidate: what the studies show, status and safety. Version 1.0, 24 September 2026. myPeptides Peptide Register. Retrieved from https://mypep.app/peptides/n-acetyl-epitalon
How pages in this register are compiled and graded is described under methodology; the full register is at peptides.
| Version | Date | Change |
|---|---|---|
| 1.0 | 2026-09-24 | Initial publication |
Last verified: 24 September 2026. Next review: on the appearance of any study of the molecule, any database or register entry naming it, or any change in the anti-doping classification.